Product
AI AGENTS
AI APPLICATIONS
OTHERS
Solutions
INDUSTRIES
Pricing
Resources
EXPLORE
ENGAGE
SUPPORT & SERVICES
About
PatSnap Eureka Platform
Agents for IP
Agents for Engineering
Agents for Life Sciences
Agents for Materials
Analytics
IP IntelligenceSynapse
Biopharma IntelligenceBio
Biosequence Search and AnalysisChemical
Chemical Structure Search and AnalysisOpen Platform
Professional Services
Customer Stories
Newsroom
Blog
Global Innovation Report
Glossary
Webinars & Training
Frontier
User Community
Trust and Security
PatentBench
LLM
Help center
Careers
Access to over 2,000,000,000 structured data points around patents, science, litigation, and tech sectors
Innovate 75% faster at 25% less cost
Cloud or on-prem for maximum privacy and control
Trusted by more than 18,000 innovators worldwide
To use , click the vertification button in the email we sent to [email protected].
This helps keep your account secure.
You should receive it shortly. Don’t forget to check your spam folder.
Unlock professional features and history
Already have an account? Log In
To start using PatSnap Eureka, click the verification button in the email we sent to .
This helps keep your account secure.
Haven't received it? Check your spam folder.
Thoughtfully curated series offering valuable insights for innovation professionals
Article | Report Sasanlimab, Pfizer's subcutaneous PD-1 inhibitor, targets BCG-unresponsive NMIBC. Explore the JAVELIN Bladder RACE program, PDUFA status, and what analysts need to know.
Article | Report Map the 2026 EV thermal runaway prevention landscape: AI early warning, BTMS, fire suppression, and key patent trends from 2017–2026. Research from PatSnap.
Article | Report How R&D teams use structured analogy methods—TRIZ, biomimicry, design-by-analogy—to find breakthrough solutions from unrelated engineering domains.
Article | Report How machine learning is transforming materials discovery in 2026: property prediction, synthesis optimization, and the key platforms powering R&D breakthroughs.
Article | Report Tezepelumab (Tezspire) is advancing into COPD clinical trials. Explore the TSLP biology, AstraZeneca/Amgen strategy, and what Phase III expansion means for obstructive lung disease.
Article | Report A 2026 technology landscape of biochar soil carbon sequestration: patent gaps, key research clusters, geographic hotspots, and strategic IP implications for PyCCS.
Article | Report Analyse 70+ patents on CMC turbine blade technology: SiC-SiC architectures, root attachment IP, top assignees, and five emerging directions shaping propulsion in 2026.
Article | Report Savolitinib targets MET-driven papillary renal cell carcinoma in Phase III trials. Explore the AstraZeneca/Hutchmed registration strategy, mechanism, and IP landscape.
Article | Report How AI is reshaping the way engineers identify and evaluate cross-industry technology transfer opportunities — from patent mining to innovation scouting.
Article | Report Explore the 2026 LCA landscape for cobalt, lithium, and nickel battery supply chains — methodologies, environmental impact modeling, and patent intelligence.
Article | Report How engineers use patent citation mapping to identify seminal inventions in emerging tech. Covers forward & backward citation analysis, network methods, and R&D strategy.
Article | Report Gefurulimab and AstraZeneca's C5 complement inhibitor enter Phase II/III in myasthenia gravis. How do they compare to efgartigimod and ravulizumab?
Article | Report Explore the 2026 nanocellulose composite materials landscape for packaging and structural applications — patent trends, key players, and innovation intelligence.
Article | Report AEMWE patent and literature landscape 2026: membrane chemistry, non-PGM catalysts, scale-up milestones, and strategic IP white space for green hydrogen.
Article | Report Giredestrant (GDC-9545) enters Phase III in early HR+ breast cancer via Roche's evERA trial. Analyse the oral SERD competitive landscape: imlunestrant, camizestrant, elacestrant & more.